Human tumour vessel heterogeneity in ovarian cancer and its association with response to neoadjuvant chemotherapy

Emmanuel M. Gabriel; Kulkaew Sukniam; Kyle Popp; Gabrielle Kowkabany; Harsheen K. Manaise; Kristopher Attwood; Anthony George; Qihui Zhai; Sanjay P. Bagaria; Keith L. Knutson; Joseph J. Skitzki; Matthew W. Robertson; Tri A. Dinh

doi:10.1002/ctm2.1633

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (4) : e1633 DOI: 10.1002/ctm2.1633

LETTER TO THE JOURNAL

Human tumour vessel heterogeneity in ovarian cancer and its association with response to neoadjuvant chemotherapy

Author information +

History +

PDF

Cite this article

Download citation ▾

Emmanuel M. Gabriel, Kulkaew Sukniam, Kyle Popp, Gabrielle Kowkabany, Harsheen K. Manaise, Kristopher Attwood, Anthony George, Qihui Zhai, Sanjay P. Bagaria, Keith L. Knutson, Joseph J. Skitzki, Matthew W. Robertson, Tri A. Dinh. Human tumour vessel heterogeneity in ovarian cancer and its association with response to neoadjuvant chemotherapy. Clinical and Translational Medicine, 2024, 14(4): e1633 DOI:10.1002/ctm2.1633

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Hempel C, Johnsen KB, Kostrikov S, Hamerlik P, Andresen TL. Brain tumour vessels-a barrier for drug delivery. Cancer Metastasis Rev. 2020;39:959-968.

[2]	Azzi S, Hebda JK, Gavard J. Vascular permeability and drug delivery in cancers. Front Oncol. 2013;3:211.

[3]	Narang AS, Varia S. Role of tumour vascular architecture in drug delivery. Adv Drug Deliv Rev. 2011;63:640-658.

[4]	Gabriel EM, Kim M, Fisher DT, et al. A pilot trial of intravital microscopy in the study of the tumour vasculature of patients with peritoneal carcinomatosis. Sci Rep. 2021;11:4946.

[5]	Gabriel EM, Kim M, Fisher DT, et al. Dynamic control of tumour vasculature improves antitumor responses in a regional model of melanoma. Sci Rep. 2020;10:13245.

[6]	Sood AK, Fletcher MS, Zahn CM, et al. The clinical significance of tumour cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther. 2002;1:661-664.

[7]	Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumour vasculature. Adv Drug Deliv Rev. 2011;63:623-639.

[8]	Bouzin C, Feron O. Targeting tumour stroma and exploiting mature tumour vasculature to improve anti-cancer drug delivery. Drug Resist Updat. 2007;10:109-120.

[9]	Baronzio G, Parmar G, Baronzio M. Overview of methods for overcoming hindrance to drug delivery to tumors, with special attention to tumor interstitial fluid. Front Oncol. 2015;5:165.

[10]	Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng. 2011;2:281-298.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.